Compositions containing HMG Co-A reductase inhibitors and policosanol
US6890941B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 3, 2003 |
| Grant date | May 10, 2005 |
| Priority date | — |
| Expiry date | Dec 3, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides pharmaceutical compositions, methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concentration, for example, hypercholesterolemia, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, cholesterol gallstones, and lipid storage diseases. The compositions, methods, combinations, and kits of the present invention are pharmaceutical compositions comprising atherapeutically effective amount of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, and compound that inhibits cholesterol synthesis at a point between the formation of acetate and mevalonate. A typical pharmaceutical composition of the invention contains and effective amount of atorvastatin and an effective amount of policosanol.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.